Federal prosecutors say two men smuggled thousands of fake Ozempic pens from unauthorized makers in China into the U.S. and sold them cheap to drug distributors. One of the men, Swapnadip Roy, 33, is now in an American courtroom after being extradited from Italy, meaning Italian authorities arrested him and handed him over to the U.S. to face the charges.
Story Highlights
- Swapnadip Roy made his first appearance in federal court in Tampa on Tuesday, September 29, after his extradition from Italy.
- A grand jury indicted Roy and Vicky Ramancha, 37; Ramancha is still at large.
- Prosecutors say the fake pens came from China with fake labels, inserts and needles.
- Each man faces up to 71 years in prison if convicted.
Indictment Alleges A Cross-Border Counterfeit Pipeline
The indictment charges each man with one count of conspiracy to commit smuggling and to defraud the U.S., three counts of smuggling, and two counts of selling counterfeit drugs and holding them for sale. Prosecutors say the scheme ran from July 2023 through April 2024. The men obtained fake Ozempic from unauthorized sources in China and sold it to U.S. distributors at low prices to move volume. Prosecutors say the pair wrote that “if you want the product cheap, you have to understand that there are some corners being cut.”
The fake pens came in counterfeit packaging with fake inserts, labels and needles made to look like real Ozempic, which is made by Novo Nordisk. Ozempic, a brand of semaglutide, is used for diabetes and is widely sought for weight loss. In March 2024, prosecutors say, Ramancha helped arrange the delivery of about 11,000 units of the fake drug to a warehouse in Ohio. Thousands more went to companies in Florida.
Status Of The Defendants And The Legal Process
Roy made his first appearance in U.S. District Court in Tampa, in the Middle District of Florida, on Tuesday, September 29. Ramancha is still at large. Both men are Indian citizens who lived in Dubai. The charges are accusations, and both men are presumed innocent unless proven guilty in court. If convicted, each faces a maximum of 71 years in prison.
The Food and Drug Administration’s Office of Criminal Investigations led the case, with prosecutors from the Justice Department’s Criminal Division and the Middle District of Florida. “Counterfeit prescription drugs — especially common ones — threaten the health and safety of every American,” Assistant Attorney General A. Tysen Duva said. Justin Green, an assistant commissioner at the FDA, added: “Drug safety and quality do not begin or end at the U.S. border.”
Why Counterfeit Ozempic Keeps Showing Up
The Food and Drug Administration issued a public warning about counterfeit Ozempic in December 2023. Prosecutors say the men kept selling fakes after that warning. People inject these pens, so a fake pen can put a patient at real risk. Acting FDA Commissioner Kyle Diamantas called counterfeit products in the American drug supply “a direct threat to public health.”
High demand and high prices have drawn illegal sellers who pose as bargain suppliers. The Food and Drug Administration urges pharmacies to buy only from authorized distributors and to check packaging closely. Lawful supply chains are built with checks for this reason. When those checks fail, fake drugs can slip into trusted channels. In this case, prosecutors say, the fakes reached a warehouse in Ohio and companies in Florida.
Broader Frustration: Safety Gaps And A System Under Strain
Patients who do everything right — see a doctor, fill a prescription, follow the label — count on the pen in the box being real. Prosecutors say this scheme sold fakes to distributors, the middlemen who supply pharmacies and clinics. That is the weak point this case targets. Every step matters, from import checks at the border to wholesale buying to the pharmacy counter.
Federal agencies say they are pursuing counterfeiters and warning the public. Lasting fixes likely require stronger import controls, faster tracing tools for pharmacies, and clear penalties for companies that cut corners. Consumers can help by filling prescriptions only at licensed pharmacies, but the burden cannot rest on patients alone. Trust grows when the system catches the fakes before they reach the counter.
What To Watch Next
Roy’s case now moves through federal court in Tampa. Watch for court filings that show how investigators linked shipments, payments and packaging to the two men. Look for any plea deal or cooperation, which can show how wide a network runs. Watch, too, for news on the search for Ramancha and for new FDA alerts about fake Ozempic and guidance to pharmacies.
Sources:
cbsnews.com, justice.gov, fda.gov, cnbc.com, hoodline.com, firstpost.com, reuters.com, hindustantimes.com